Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 3

PMID 24086526

Citations 24

Authors

Junaid Abdulghani

Joshua E Allen

David T Dicker

Yingqiu Yvette Liu

David Goldenberg

Charles D Smith

Robin Humphreys

Wafik S El-Deiry

Affiliations

Soon will be listed here.

Abstract

Background: Approximately half of tumor cell lines are resistant to the tumor-selective apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (Apo22L/TRAIL). Previously, we showed that combining Apo2L/TRAIL with sorafenib, a multikinase inhibitor, results in dramatic efficacy in Apo2L/TRAIL-resistant tumor xenografts via inhibition of Mcl-1. Soluble Apo2L/TRAIL is capable of binding to several surface receptors, including the pro-apoptotic death receptors, DR4 and DR5, and decoy receptors, DcR1 and DcR2. Monoclonal antibodies targeting either of these death receptors are being investigated as antitumor agents in clinical trials. We hypothesized that sorafenib and Apo2L/TRAIL or Apo2L/TRAIL death receptor agonist (TRA) antibodies against DR4 (mapatumumab) and DR5 (lexatumumab) will overcome resistance to Apo2L/TRAIL-mediated apoptosis and as increase antitumor efficacy in Apo2L/TRAIL-sensitive solid tumors.

Methodology/principal Findings: We found that Apo2L/TRAIL or TRA antibodies combined with sorafenib synergistically reduce cell growth and increase cell death across a panel of solid tumor cell lines in vitro. This panel included human breast, prostate, colon, liver and thyroid cancers. The cooperativity of these combinations was also observed in vivo, as measured by tumor volume and TUNEL staining as a measure of apoptosis. We found that sorafenib inhibits Jak/Stat3 signaling and downregulates their target genes, including cyclin D1, cyclin D2 and Mcl-1, in a dose-dependent manner.

Conclusions/significance: The combination of sorafenib with Apo2L/TRAIL or Apo2L/TRAIL receptor agonist antibodies sensitizes Apo2L/TRAIL-resistant cells and increases the sensitivity of Apo2L/TRAIL-sensitive cells. Our findings demonstrate the involvement of the Jak2-Stat3-Mcl1 axis in response to sorafenib treatment, which may play a key role in sorafenib-mediated sensitization to Apo2L/TRAIL.

Citing Articles

Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas.

Mortensen A, Imgenberg-Kreuz J, Spiegelberg D, Botling J, Nestor M Heliyon. 2023; 9(12):e22594.

PMID: 38076095 PMC: 10709381. DOI: 10.1016/j.heliyon.2023.e22594.

The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer.

Pimentel J, Zhou J, Wu G Cancers (Basel). 2023; 15(10).

PMID: 37345089 PMC: 10216286. DOI: 10.3390/cancers15102752.

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy.

Kundu M, Greer Y, Dine J, Lipkowitz S Cells. 2022; 11(23).

PMID: 36496977 PMC: 9739296. DOI: 10.3390/cells11233717.

Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling.

Kim E, Lee W, Oh H Transl Cancer Res. 2022; 11(8):2553-2561.

PMID: 36093532 PMC: 9459640. DOI: 10.21037/tcr-21-1853.

BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.

Busche S, John K, Wandrer F, Vondran F, Lehmann U, Wedemeyer H Cell Death Dis. 2021; 12(8):736.

PMID: 34312366 PMC: 8313681. DOI: 10.1038/s41419-021-04020-z.

References

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Hall M, Cleveland J . Clearing the TRAIL for Cancer Therapy. Cancer Cell. 2007; 12(1):4-6. DOI: 10.1016/j.ccr.2007.06.011. View

Bhattacharya S, Ray R, Johnson L . STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005; 392(Pt 2):335-44. PMC: 1316269. DOI: 10.1042/BJ20050465. View

Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G . Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 2008; 172(6):1717-28. PMC: 2408430. DOI: 10.2353/ajpath.2008.071054. View

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D . Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66(24):11851-8. DOI: 10.1158/0008-5472.CAN-06-1377. View

Erovic B, Pelzmann M, Grasl M, Pammer J, Kornek G, Brannath W . Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res. 2005; 11(24 Pt 1):8632-6. DOI: 10.1158/1078-0432.CCR-05-1170. View

Abdulghani J, El-Deiry W . TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010; 14(10):1091-108. DOI: 10.1517/14728222.2010.519701. View

Bromberg J, Wang T . Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009; 15(2):79-80. PMC: 3684978. DOI: 10.1016/j.ccr.2009.01.009. View

Levy D, Darnell Jr J . Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002; 3(9):651-62. DOI: 10.1038/nrm909. View

10.

Park C, Moon D, Ryu C, Choi B, Lee W, Kim G . Beta-sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis. Acta Pharmacol Sin. 2008; 29(3):341-8. DOI: 10.1111/j.1745-7254.2008.00761.x. View

11.

Berishaj M, Gao S, Ahmed S, Leslie K, Al-Ahmadie H, Gerald W . Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007; 9(3):R32. PMC: 1929096. DOI: 10.1186/bcr1680. View

12.

Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C . MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008; 27(27):3845-55. DOI: 10.1038/onc.2008.6. View

13.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

14.

Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y . Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol. 2010; 12(7):687-700. PMC: 2940669. DOI: 10.1093/neuonc/nop069. View

15.

Kane R, Farrell A, Saber H, Tang S, Williams G, Jee J . Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006; 12(24):7271-8. DOI: 10.1158/1078-0432.CCR-06-1249. View

16.

Kischkel F, Lawrence D, Chuntharapai A, Schow P, Kim K, Ashkenazi A . Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000; 12(6):611-20. DOI: 10.1016/s1074-7613(00)80212-5. View

17.

Wang W, El-Deiry W . Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther. 2003; 2(2):196-202. DOI: 10.4161/cbt.2.2.347. View

18.

Allen J, Ferrini R, Dicker D, Batzer G, Chen E, Oltean D . Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther. 2012; 11(10):2087-95. DOI: 10.1158/1535-7163.MCT-12-0366. View

19.

Wakelee H, Patnaik A, Sikic B, Mita M, Fox N, Miceli R . Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2009; 21(2):376-381. PMC: 2813303. DOI: 10.1093/annonc/mdp292. View

20.

Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K . STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999; 189(1):63-73. PMC: 1887683. DOI: 10.1084/jem.189.1.63. View